SCHEMBL95889

SCHEMBL95889

[CH2]c1ccc(NC(=O)C2CCCCC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.74
HPGD P15428 1/20 0.69
LMNA P02545 3/20 0.59
MAPT P10636 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
RAB9A P51151 1/20 0.58
ENPP3 O14638 2/20 0.57
ENPP1 P22413 2/20 0.57
ALDH1A1 P00352 1/20 0.57
STS P08842 1/20 0.57
PTPN2 P17706 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NAMPT P43490 1/20 0.56
NPC1 O15118 1/20 0.55
ENPP2 Q13822 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94785 0.98 PTPN1 (0.71) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL28656982 0.91 PTPN1 (0.89) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL125695 0.91 PTPN1 (0.89) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL22919689 0.84 PTPN1 (0.72) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL29057710 0.84 PTPN1 (0.77) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL9851155 0.84 PTPN1 (0.77) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL678484 0.82 PTPN1 (0.74) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL8363734 0.82 PTPN1 (0.74) PTPN1HPGDLMNAMAPTNPSR1
SCHEMBL8296637 0.82 PTPN1 (0.74) PTPN1HPGDLMNAMAPTSMN1; SMN2
SCHEMBL1785803 0.82 PTPN1 (0.74) PTPN1HPGDLMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB PTPN1 1236/4885HPGD 2146/4885LMNA 3740/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 PTPN1 1691/4885HPGD 2322/4885LMNA 4860/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 PTPN1 1691/4885HPGD 2322/4885LMNA 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.